Based on these in vivo and in vitro studies, a clinical trial was performed to study the efficacy of IGF-1 in the treatment of SNHL (University Hospital Medical Information Network Clinical Trials Registry under trial registration number UMIN000000936; Nakagawa et al., 2010, 2012). The gene discussed is IGF1; the disease is sensorineural hearing loss disorder.